We hope that this Project will bring with it:

• Improve the life expectancy of the oncology population.
• Know a patient's likely therapeutic response.
• Reduce government treatment costs.
• Promote the implementation of Precision Medicine.

We are developing four lines of research and two associated investigations, which through the recruitment of tumor samples from cancer patients, will carry out genomic studies by massively parallel sequencing (NGS), in vitro and in silico studies.

In addition to promoting activities such as workshops, courses, laboratories, seminars and/or reports related to our research.

1. Improve understanding and scientific evidence regarding the usable cancer genome.
2. Identify and validate usable biomarkers that indicate response to cancer therapies in use nationwide.
3. Contribute to the National Biobank Network in its technical, legal, and ethical regulation.

We are a multidisciplinary group with national and international collaboration networks with world-renowned companies focused on mutation research in oncology and oncology genomics. Considered one of the most advanced molecular diagnostic laboratories in Europe, it is internationally recognized for its extensive technology and human resources.

Eurofins Genoma Group, a leading provider of analytical services with an international network of over 800 laboratories in 47 countries across Europe, North and South America and Asia-Pacific.

Innovative technologies, quality, professionalism, and expertise: Eurofins Genoma Group is the Italian and European reference point for molecular diagnostics.

Signatera ™

Transforming cancer management with personalized testing

As a pioneer and trusted leader in the field of MMR testing, Signatera™ has been featured in over 125 peer-reviewed publications and has currently tested over 300,000 patients.

Signatera™ is a unique blood test, personalized for each patient using their own tumor tissue. It is used to detect cancer earlier and improve treatment response compared to standard-of-care tools.

A doctor may prescribe Signatera™, along with other routine checkups, to determine:

• If there are signs of cancer remaining in the body.
• If treatment (e.g., chemotherapy, radiation, immune checkpoint inhibitors) is working.
• If the cancer might come back.

Order a test kit at info@oncogenoma.com

Transforming cancer management with personalized testing.

Signatera™ is a highly sensitive, personalized molecular test for residual disease (MRD) using circulating tumor DNA (ctDNA), tailored for each patient to help identify relapses earlier than standard of care tools.

Signatera™ is a special type of MRD test designed using your tumor. It's personalized just for you. Here's what it can do:

• Identify if there are any signs of cancer remaining in your body after surgery or definitive therapy.
• Determine if you will benefit from additional therapy after surgery.
• Determine if your treatment (e.g., chemotherapy, radiation) is working.
• Find out if your cancer might return before standard care tools.

Patients often have questions about care after a cancer diagnosis or treatment. You should talk to your care team about how to check if treatment is working and how to watch for signs that the cancer may return. Signatera™ is a test that looks for tiny pieces of tumor DNA in the blood. It is personalized, using your own tumor tissue.

After each test is submitted, your oncologist will discuss the results with you. It may take about 3-4 weeks to get the first result, but subsequent tests usually only take 7-10 days. Depending on the type of cancer, your doctor may use surveillance tools to monitor your cancer treatment and whether it is working. Signatera™ works best when used regularly over time. Your doctor may also discuss other tests or treatments to monitor your cancer and ensure you are receiving the best care.

It is important to ask your doctor any questions you have about your test results and their possible impact on your treatment plan.

On the advice of your doctor or after a visit with one of our oncologists, Secretarial Service: Toll-free number 800.019.330.

The Domus Salutis Clinic in Legnago, Verona, offers oncology consultations for second opinions from our clinical and oncology experts.

We offer high-quality consultations. To ensure proper preparation for the consultation, we ask that you submit a summary of your medical history and recent medical and diagnostic reports.

Second opinion in the presence of the patient or via Zoom (or similar systems):

Second opinion in the absence of the patient: study and analysis of clinical documentation

Second opinion follow-up:

The second opinion consultation includes: review of the provided materials, taking the patient's medical history, examining the patient (if present), reviewing the imaging materials (diagnostic tests), and preparing a written summary to bring with you at the end of the consultation or send to the patient electronically in the following days. The consultation lasts approximately 1 hour.

The pathologies treated include:

• lymphomas;
• leukemias;
• gynecological tumors;
• thyroid tumors;
• brain tumors;
• breast cancer;
• gastrointestinal tumors;
• urogenital tumors;
• skin tumors, melanomas.

From the date of receipt of the complete dossier (including any attachments and/or paper documentation) and after payment, the clinic undertakes to schedule an appointment and provide a written response to the clinical question within 15 working days.

If the response takes more than 15 days or if the clinic is unable to process the request, the amount paid will be refunded.

A second medical evaluation is an important aid in making a decision. We support you with expert and professional advice.

Second Opinion is a unique and personalized service, which focuses on the specific characteristics of the patient's tumor

oncogenoma@gmail.com

Toll-free number 800.019.330

High-dose vitamin C (ascorbic acid) and its potential role in cancer treatment have been studied for decades. Current scientific evidence is mixed: some results are promising (especially with intravenous administration), but there is still no definitive proof that high-dose vitamin C cures cancer.